Company's Profile
Mesoblast Limited, an Australian-based company, focuses on developing late-stage product candidates using proprietary mesenchymal lineage cell therapy platforms. Their flagship products, Remestemcel-L and Rexlemestrocel-L, are in late-stage development for treating various systemic inflammatory diseases and chronic conditions such as acute Graft versus Host Disease, respiratory distress syndrome, chronic heart failure, and low back pain due to degenerative disc disease. Additionally, Mesoblast has commercialized two products in Japan and Europe and established partnerships for Phase III assets in Europe and China.